We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A group of Estonian psychiatrists and civic activists believe that allowing the therapeutic use of currently prohibited ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on MNMD stock, giving a Buy rating yesterday.Invest with Confidence: ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

Spravato is classified as a Schedule III controlled ... dizziness, headache, anxiety, vomiting, feeling drunk, increased blood pressure, and sedation. No new safety signals were identified in ...